Active	Status	Sponsor type	Region	Phase	Filter
3 Active 2 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schepper, Jo De
RECONFIRM, NCT05202678: - Study of AGN1 LOEP in Patients with Osteoporosis	Recruiting	N/A	150	Europe	AGN1 LOEP	AgNovos Healthcare, LLC	Osteoporosis	12/25	12/26
NCT04511364: CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP	Active, not recruiting	N/A	60	Europe	Clinical imaging is performed during the 24 and 60 month follow-up visits	AgNovos Healthcare, LLC	Osteoporosis	12/25	12/25
Kerkhove, Charlotte Van de
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC	Active, not recruiting	1/2	73	Europe	PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed	PDC*line Pharma SAS	Non Small Cell Lung Cancer	07/24	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schepper, Jo De
RECONFIRM, NCT05202678: - Study of AGN1 LOEP in Patients with Osteoporosis	Recruiting	N/A	150	Europe	AGN1 LOEP	AgNovos Healthcare, LLC	Osteoporosis	12/25	12/26
NCT04511364: CONFIRM EXTENSION - Long-term Follow-up Study of Patients Treated with AGN1 LOEP	Active, not recruiting	N/A	60	Europe	Clinical imaging is performed during the 24 and 60 month follow-up visits	AgNovos Healthcare, LLC	Osteoporosis	12/25	12/25
Kerkhove, Charlotte Van de
PDC-LUNG-101, NCT03970746 / 2018-002382-19: Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC	Active, not recruiting	1/2	73	Europe	PDC*lung01, Keytruda Injectable Product, Pembrolizumab, Alimta Injectable Product, Pemetrexed	PDC*line Pharma SAS	Non Small Cell Lung Cancer	07/24	12/25